La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Galecto a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Galecto..

Galecto (NASDAQ:GLTO) Azioni, Catena delle Opzioni

Galecto

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Galecto Inc

Dynatrace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 6.95 million shares sold short, which is 2.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dynatrace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dynatrace has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dynatrace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dynatrace's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Dynatrace's Recent Short Interest

Carrier Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 10.17 million shares sold short, which is 1.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Carrier Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carrier Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carrier Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Carrier Global's peer group average for short interest as a percentage of float is 3.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CARR

(CARR) - Analyzing Carrier Global's Short Interest

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is &#8220;undervalued,&#8221; but he is not going to <a href="https://www.benzinga.com/quote/MO/guidance">recommend tobacco stocks</a>.
On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. It beat the street view of $1.35. Quarterly sales of $5.334 billion (+1.3%) beat the analyst consensus estimate of $5.326 billion.
Cramer recommended selling Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
Super Micro Computer filed a FormNT 10-Q with the Securities and Exchange Commission, indicating that it's unable to file its 2025 fiscal-year first-quarter earnings on time.
When asked about The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), he said, &#8220;I prefer not to be in a stock that is going to lose a lot of money for a long time.&#8221;
According to Reuters, the company reportedly begins issuing layoff notices to employees affected by a major restructuring plan. The plan, which aims to reduce Boeing's global workforce by 17,000 jobs—approximately 10% of its total—comes as the heavily indebted aerospace <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41950702/boeing-reportedly-plans-furloughs-whats-going-on">giant seeks to cut costs</a>.
Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) has &#8220;broken down severely,&#8221; Cramer said. &#8220;If Robert F. Kennedy Jr. is going to be the head of HHS, then it's going to hurt a lot of vaccines, it could hurt a lot of their business.&#8221;
On Nov. 7, the company posted better-than-expected results for its fourth quarter.
&#8220;They have a lot of phase one stuff, and phase one is might early. Too early for me to bet on,&#8221; Cramer said when asked about IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>).
On Nov. 4, IDEAYA Biosciences reported a quarterly loss of 60 cents per share, compared to consensus estimates of a loss of 64 cents per share.
&#8220;I just don't know what is wrong,&#8221; Cramer said about AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>). &#8220;My god is this thing going lower.&#8221;
On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
Price Action:
<ul>
<li>Altria shares rose 0.3% to settle at $55.39 on Thursday.</li>
<li>Super Micro Computer shares dipped 11.4% to close at $18.01.</li>
<li>Boeing shares fell 1.3% to settle at $138.14 during the session.</li>
<li>Becton Dickinson shares fell 1.8% to close at $227.17 on Thursday.</li>
<li>IDEAYA Biosciences shares fell 3.4% to settle at $29.47 during the session.</li>
<li>AstraZeneca shares fell 0.4% to close at $65.04 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

News

Markets

Media

IDYA

SMCI

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It

October retail sales in the United States grew more than expected and their annual growth recorded the highest pace since July 2024, suggesting that U.S. consumers showed continued resilience in their spending habits ahead <a href="https://www.benzinga.com/topic/2024-election">of the presidential elections. </a>
Retail and food services sales reached $718.9 billion in October, marking a 0.4% increase over September. The figure is seasonally adjusted but not adjusted for inflation and is an advance estimate released by a government agency Friday. 
The monthly growth figure topped market expectations for a 0.3% increase, according to consensus estimates from TradingEconomics, but represented a deceleration from the upwardly revised 0.8% increase recorded in September.
<h3 class="wp-block-heading">Electronics Shopping Rebounds In October</h3>
On a year-over-year basis, retail sales grew by a robust 2.8%, the highest in three months and the second-strongest since April, up from the upwardly revised 2% in September. 
Excluding motor vehicles and parts, retail sales rose by just 0.1% month-over-month, down from the upwardly revised 1% growth in September, missing expectations of 0.3%. When stripping out gasoline, motor vehicles, and parts, sales inched 0.1% up in October, a noticeable deceleration from the 1.2% growth seen the previous month.
Within spending categories, electronic and appliance stores recorded the largest monthly gain, with sales increasing 2.3%, rebounding significantly from the 2.9% decline in September. 
Motor vehicle and parts dealers saw a 1.6% rise, accelerating from the previous 0.2% growth. 
On the other hand, miscellaneous store retailers registered the steepest monthly decline, with sales contracting 1.6%, followed closely by furniture and home furniture stores, which saw sales fall 1.3%.
Before the report's release, traders were pricing in a 58% probability of a 25-basis-point rate cut at the Federal Reserve's December meeting, according to the CME FedWatch Tool. 
Those expectations shifted substantially downward from about 80% after Fed Chair Jerome Powell stated on Thursday that the Federal Reserve is not in a hurry<a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates"> to lower interest rates. </a>
Powell also emphasized that the strength of the U.S. economy allows policymakers to approach rate decisions carefully, suggesting the potential for a pause in rate cuts.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a></li>
</ul>
Photo via Shutterstock.

Retail Sales

Econ #s

Economics

October Retail Sales Top Expectations As US Consumers Increase Tech Spending

On Friday, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 <a href="https://www.benzinga.com/pressreleases/24/11/g42000231/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urtic" target="_blank" rel="noreferrer noopener">antihistamine treatment</a>.
The target action date for the FDA decision is April 18, 2025.
Data from the multi-study LIBERTY-CUPID phase 3 clinical program (<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-07-29-05-00-00-2270858" rel="noreferrer noopener">Study A</a>,&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-18-06-00-00-2387700" rel="noreferrer noopener">Study B</a>, and&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-11-05-05-00-2944239" rel="noreferrer noopener">Study C</a>) for Dupixent in CSU support the resubmitted supplemental marketing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41945225/regeneron-sanofis-dupixent-approval-signals-major-treatment-breakthrough-for-smokers-lung-disease" rel="noreferrer noopener">Regeneron/Sanofi&#8217;s Dupixent Approval Signals Major Treatment Breakthrough For Smokers&#8217; Lung Disease</a>
Earlier this year, Japan was the first country in the world to&nbsp;approve&nbsp;and launch Dupixent for adult and adolescent CSU patients based on the results <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">from Study A</a>.
The supplemental marketing adds results from Study C, conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naïve patients, met its primary and key secondary endpoints, confirming the results of the previous Study A.
Results showed that Dupixent significantly reduced itch and urticaria activity (itch and hives).
In March 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670" rel="noreferrer noopener">accepted</a> the supplemental marketing application for Dupixent&nbsp;(dupilumab) to treat adults and adolescents with chronic spontaneous urticaria, with the target action date for the FDA decision of October 22, 2023.
In October 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252" rel="noreferrer noopener">issued</a> a Complete Response Letter for the supplemental Biologics License Application and stated that additional efficacy data are required to support approval.
It did not identify any issues with safety or manufacturing.
CSU is a chronic inflammatory skin disease driven partly by type-2 inflammation, which causes sudden hives and recurring itch.
CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control urticaria symptoms.
More than 300,000 people in the US suffer from CSU that is inadequately controlled by antihistamines.
Price Action: REGN stock closed at $782.51 on Thursday, and SNY stock is up 1.09% at $48.34 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape" target="_blank" rel="noreferrer noopener">UnitedHealth&#8217;s Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

REGN

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

WIIM

OneStream shares are trading lower after the company announced a 15 million class A common stock secondary offering.

InMed Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

Earnings

Know Labs FY24 EPS  $(0.20) vs $(0.41) YoY

Company's Rapid Alcohol-Reducing Beverage, Sure Shot, to be Sold in 192 Stores Across Nevada, Arizona, and California
JUPITER, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new agreement with a leading national grocery chain to sell its convenient, newly branded 4 oz. Sure Shot beverages in select stores across the Southwest. This chain boasts over 2,200 stores nationwide, making them a significant player in the grocery industry.
This strategic launch in 192 stores across Nevada, Arizona, and California represents a significant milestone in Safety Shot's growth strategy. It provides access to a substantial and rapidly growing alcohol beverage market and marks a key step towards the Company's goal of nationwide distribution.

SHOT

Safety Shot Announced A New Agreement With A Leading National Grocery Chain To Sell Its Convenient, Newly Branded 4 Oz. Sure Shot Beverages In Select Stores Across The Southwest

Evercore ISI Group analyst Duane Pfenningwerth downgrades Diamondrock Hospitality (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) from Outperform to In-Line and maintains the price target from $10.5 to $10.5.

Downgrades

Price Target

Analyst Ratings

Evercore ISI Group Downgrades Diamondrock Hospitality to In-Line, Maintains Price Target to $10.5

RVYL

Ryvyl shares are trading lower. HC Wainwright & Co. reiterated a Neutral rating on the stock.

<a href="https://www.globenewswire.com/Tracker?data=oitox4x61cysgmwWmH-4y0XEjZKDx7vc9SYpYpngH33pFS6I3IlY-q-LsjR9lIzyVSYOkq29dQRMXutaPBuvrmxtA0l3Px7d-VkLvq27Yf5vY5uqf3Do5mhfCjwAUgGo">SeaStar Medical Holding Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE&#x2122; to a third hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis.

SeaStar Medical Reaches Milestone Of 100th QUELIMMUNE Commercial Device As Shipments Begin To Its Third Hospital Customer

Lument Finance Trust shares are trading higher following a Q3 earnings beat.

SPPL

SIMPPLE shares are trading higher after the company announced a $400,000 contract to supply autonomous cleaning robots at Singapore's International Airport Terminal.

SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) reported quarterly losses of $(0.25) per share. This is a 74.75 percent increase over losses of $(0.99) per share from the same period last year. The company reported $881.69 thousand in sales this quarter. This is a 34.66 percent decrease over sales of $1.35 million the same period last year.

SBET

SharpLink Gaming Q3 EPS $(0.25) Up From $(0.99) YoY, Sales $881.69K Down From $1.35M YoY

LIFW

MSP Recovery shares are trading lower. The company reported Q3 financial results.

BTOC

Armlogi Q1 Total Revenue $42.5M, Up 3% YoY; EPS $(0.11) vs $0.07 YoY

SharpLink Gaming Q3 Revenue $881.690K Down From $1.349M YoY

SIMPPLE Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) ("SIMPPLE" or "the Company"), a leading technology provider and innovator in the facilities management (FM) sector, today announced that the Company has been awarded a $400,000 contract for the supply of autonomous cleaning robotics at one of Singapore's international airport terminals.
This robot tender success comes as part of the airport's renewal program and complements the existing fleet of autonomous cleaning robots across its airport terminals, where the Company has been one of two incumbent robotic suppliers for the past five years.
The results of the ongoing tender exercise for the remaining airport terminals will be announced in the near future, with an expected aggregate contract value of $1.8 million.

Contracts

Global

SIMPPLE Wins $400,000 Contract To Supply Autonomous Cleaning Robots At Singapore's International Airport Terminal; The Results Of The Ongoing Tender Exercise For The Remaining Airport Terminals Will Be Announced In The Near Future, With An Expected Aggregate Contract Value Of $1.8M

PHIO

Phio Pharma shares are trading higher. The company reported Q3 financial results.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galecto (NASDAQ:<a href="https://investorplace.com/stock-quotes/glto-stock-quote/">GLTO</a>) just reported results for the first quarter of 2024.<ul><li>Galecto reported earnings per share of -20 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/glto-stock-earnings-galecto-for-q1-of-2024/">GLTO Stock Earnings: Galecto Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLTO Stock Earnings: Galecto Beats EPS for Q1 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sagimet Biosciences, Inc. Class A (SGMT – Research R...

Analysts' Top Healthcare Picks: Sagimet Biosciences, Inc. Class A (SGMT), Galecto (GLTO)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galecto (NASDAQ:<a href="https://investorplace.com/stock-quotes/glto-stock-quote/">GLTO</a>) just reported results for the second quarter of 2024.<ul><li>Galecto reported earnings per share of -20 cents. This was above the analyst estimate for EPS of -31 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/glto-stock-earnings-galecto-for-q2-of-2024/">GLTO Stock Earnings: Galecto Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLTO Stock Earnings: Galecto Beats EPS for Q2 2024

Galecto announces 1-for-25 reverse stock split

The latest update is out from Galecto ( ($GLTO) ). Galecto, Inc. successfully acquired global rights to BRM-1420, a promising treatment for acute m...

Galecto Expands Oncology Portfolio with Strategic Acquisition

Galecto ( ($GLTO) ) has issued an announcement. Galecto, Inc. has strengthened its Board of Directors by appointing Dr. Amy Wechsler, a distinguish...

Galecto Appoints Dr. Amy Wechsler to Board

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Galecto (GLTO – Research Report), with a price target of $10.00. ...

Oppenheimer Sticks to Its Buy Rating for Galecto (GLTO)

Galecto reports Q3 results

Galecto, Inc. ( ($GLTO) ) has released its Q3 earnings. Here is a breakdown of the information Galecto, Inc. presented to its investors. Galecto, I...

Galecto, Inc. Announces Strategic Shift and Financial Overview

Galecto, Inc. (GLTO) has disclosed a new risk, in the Corporate Activity and Growth category. Galecto, Inc. faces a significant business risk follo...

Comments

Galecto

Galecto (GLTO) Opzioni

Galecto (NASDAQ:GLTO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO